High-dose LTI-03 (5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and decreased the expression of a ...

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN ... Any forward-looking statements contained in this press release speak only as of the date hereof, and CENTOGENE specifically disclaims any ...

In 2023 Cullgen completed a Series C financing led by AstraZeneca-CICC Venture Capital Partnership, and also announced a strategic partnership with Astellas Pharma Inc.

Cash Position: As of September 30, 2024, cash, cash equivalents, and marketable securities were $175.5 million. R&D Expenses ...

CyberArk (NASDAQ: CYBR), the global leader in identity security, today announced strong financial results for the third quarter ended September 30, 2024.

Please refer to today's release ... effect. In line with our strategic ambition, our D2C channel has significantly outpaced ...

Research and development (R&D) expenses (in continuing operations) for the third quarter of 2024 were $16.5 million ... made in this press release. Any such forward-looking statements represent ...

Having joined the Miracle of Sound live project as a session musician, as a songwriter, she continues to release her own ...

Second consecutive quarter of 20 ReWalk systems sold Robust growth in U.S. ReWalk pipeline of approximately 70 qualified leads for potential claim submission with Medicare and other U.S. payors MARLBO ...

The call will be archived and available there along with the company's earnings release ... the $5 billion NEVI program focused on highways, funded by the bipartisan IIJA and the 30C tax credit from ...

Ohlen goes on to use BioWare's own titles as examples, which he worked on himself for over 22 years. "At BioWare, we had two ...